Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

50 matching registry records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:42 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4CompletedINTERVENTIONAL

Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition

ClinicalTrials.gov · NCT04344717 · Registry updated: 2026-10-15

Condition / research focus: Short Bowel Syndrome; Anticoagulation
Sponsor: Universitaire Ziekenhuizen KU Leuven
Countries with listed sites: Belgium
Registry dates and results: Start: 2020-12-20. Completion: 2025-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Apixaban single dose (drug) — also listed as: Eliquis single dose
Apixaban steady-state (drug) — also listed as: Eliquis steady-state

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

University Hospitals Leuven
Leuven, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)

ClinicalTrials.gov · NCT05561647 · Registry updated: 2026-10-05

Condition / research focus: Short Bowel Syndrome (SBS)
Sponsor: Takeda
Countries with listed sites: United States
Registry dates and results: Start: 2013-08-01. Completion: 2026-08-26 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

No Intervention (other)

Where the study takes place — 1 listed sites

Takeda Pharmaceuticals, U.S.A., Inc.
Cambridge, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableActive, not recruitingOBSERVATIONAL

Registry for Participants With Short Bowel Syndrome

ClinicalTrials.gov · NCT01990040 · Registry updated: 2026-09-23

Condition / research focus: Short Bowel Syndrome
Sponsor: Shire
Countries with listed sites: United States
Registry dates and results: Start: 2014-06-23. Completion: 2032-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Shire
Lexington, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Active, not recruitingINTERVENTIONAL

A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

ClinicalTrials.gov · NCT06973304 · Registry updated: 2026-09-08

Condition / research focus: Short Bowel Syndrome
Sponsor: Takeda
Countries with listed sites: China
Registry dates and results: Start: 2025-06-26. Completion: 2027-07-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: TAK-633, A16AX08, Revestive, Gattex

Where the study takes place — 4 listed sites

Beijing Tsinghua Changgung Hospital
Changping, Beijing Municipality, China
Site recruitment: Not reported
Peking Union Medical College Hospital
Dongcheng, Beijing Municipality, China
Site recruitment: Not reported
Affiliated Jinling Hospital, Medical School of Nanjing University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Zhongshan Hospital, Xiamen University
Siming, Xiamen, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study of Teduglutide in Japanese People With Short Bowel Syndrome

ClinicalTrials.gov · NCT05023382 · Registry updated: 2026-08-07

Condition / research focus: Short Bowel Syndrome
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2021-09-01. Completion: 2026-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: TAK-633, Revestive

Where the study takes place — 1 listed sites

Takeda Selected Site
Tokyo, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED)

ClinicalTrials.gov · NCT07537686 · Registry updated: 2026-04-17

Condition / research focus: Environmental Enteric Dysfunction
Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
Countries with listed sites: No country reported
Registry dates and results: Start: 2026-07-01. Completion: 2027-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide 0.05 dose (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome

ClinicalTrials.gov · NCT07319832 · Registry updated: 2026-03-13

Condition / research focus: Short Bowel Syndrome (SBS)
Sponsor: Takeda
Countries with listed sites: China
Registry dates and results: Start: 2026-03-05. Completion: 2027-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

No Intervention (other)

Where the study takes place — 4 listed sites

Guangzhou Women And Children's Medical Center
Guangzhou, Guangdong, China
Site recruitment: Not yet recruiting
Shanghai Children's Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not yet recruiting
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Recruiting
Children's Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Site recruitment: Not yet recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

TED_ORG: Study on Short Bowel Syndrome

ClinicalTrials.gov · NCT07400783 · Registry updated: 2026-02-10

Condition / research focus: Short Bowel Syndrome (SBS)
Sponsor: Meyer Children's Hospital IRCCS
Countries with listed sites: Italy
Registry dates and results: Start: 2024-10-30. Completion: 2026-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (ALX-0600) (drug)
No Treatment Added (other)

Where the study takes place — 1 listed sites

Aou Meyer IRCSS
Florence, Florence, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients

ClinicalTrials.gov · NCT03562130 · Registry updated: 2025-09-11

Condition / research focus: Short Bowel Syndrome
Sponsor: Assistance Publique - Hôpitaux de Paris
Countries with listed sites: France
Registry dates and results: Start: 2018-07-02. Completion: 2020-07-13 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)

Where the study takes place — 1 listed sites

Hôpital Necker - Enfants malades
Paris, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

ClinicalTrials.gov · NCT05371028 · Registry updated: 2025-04-06

Condition / research focus: Short Bowel Syndrome (SBS)
Sponsor: Takeda
Countries with listed sites: Canada
Registry dates and results: Start: 2023-09-23. Completion: 2025-02-19 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Non-interventional Study (other)

Where the study takes place — 1 listed sites

Innomar Strategies
Oakville, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)

ClinicalTrials.gov · NCT02954458 · Registry updated: 2025-03-28

Condition / research focus: Short Bowel Syndrome
Sponsor: Shire
Countries with listed sites: Belgium · Canada · Finland · Italy · United Kingdom · United States
Registry dates and results: Start: 2017-01-09. Completion: 2020-11-05 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TED (drug)
SOC (other)
Syringe (device)
Needle (device)

Where the study takes place — 22 listed sites

Childrens Hospital Los Angeles - RHU
Los Angeles, California, United States
Site recruitment: Not reported
Mattel Children's Hospital UCLA
Los Angeles, California, United States
Site recruitment: Not reported
UCSF Benioff Children's Hospital
San Francisco, California, United States
Site recruitment: Not reported
Georgetown Children's Research Network
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Riley Hospital for Children
Indianapolis, Indiana, United States
Site recruitment: Not reported
Boston Children's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
The Nebraska Medical Center
Omaha, Nebraska, United States
Site recruitment: Not reported
Columbia Unversity Medical Center
New York, New York, United States
Site recruitment: Not reported
Children's Hosp. at Montefiore
The Bronx, New York, United States
Site recruitment: Not reported
Duke Medical Center
Durham, North Carolina, United States
Site recruitment: Not reported
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Site recruitment: Not reported
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Texas Children's Hospital
Houston, Texas, United States
Site recruitment: Not reported
Seattle Children's Hospital
Seattle, Washington, United States
Site recruitment: Not reported
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, United States
Site recruitment: Not reported
Cliniques Universitaires Saint-Luc
Brussels, Woluwe-Saint-Lambert, Belgium
Site recruitment: Not reported
Walter C. Mackenzie Health Science Centre
Edmonton, Alberta, Canada
Site recruitment: Not reported
The Hospital for Sick Children
Toronto, Ontario, Canada
Site recruitment: Not reported
Helsingin yliopistollinen keskussairaala
Helsinki, Finland
Site recruitment: Not reported
Ospedale Pediatrico Bambino Gesu
Roma, Italy
Site recruitment: Not reported
Great Ormond Children's Hosp
London, Greater London, United Kingdom
Site recruitment: Not reported
Birmingham Children's Hospital
Birmingham, West Midlands, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

ClinicalTrials.gov · NCT02949362 · Registry updated: 2025-03-19

Condition / research focus: Short Bowel Syndrome
Sponsor: Shire
Countries with listed sites: United Kingdom · United States
Registry dates and results: Start: 2016-12-09. Completion: 2020-07-14 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)
SOC (other)

Where the study takes place — 11 listed sites

Childrens Hospital Los Angeles - RHU
Los Angeles, California, United States
Site recruitment: Not reported
Mattel Children's Hospital UCLA
Los Angeles, California, United States
Site recruitment: Not reported
Riley Hospital for Children
Indianapolis, Indiana, United States
Site recruitment: Not reported
Boston Children's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
Children's Mercy Hospitals and Clinics
Kansas City, Missouri, United States
Site recruitment: Not reported
Children's Hospital at Montefiore
The Bronx, New York, United States
Site recruitment: Not reported
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Site recruitment: Not reported
Texas Children's Hospital
Houston, Texas, United States
Site recruitment: Not reported
Seattle Children's Hospital
Seattle, Washington, United States
Site recruitment: Not reported
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, United States
Site recruitment: Not reported
Great Ormond Children's Hospital
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older

ClinicalTrials.gov · NCT05027308 · Registry updated: 2024-05-16

Condition / research focus: Short Bowel Syndrome
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2022-01-04. Completion: 2023-09-27 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: TAK-633

Where the study takes place — 6 listed sites

University of Tsukuba Hospital
Tsukuba, Ibaraki, Japan
Site recruitment: Not reported
Tohoku University Hospital
Sendai, Miyagi, Japan
Site recruitment: Not reported
Showa University Hospital
Shinagawa-ku, Tokyo, Japan
Site recruitment: Not reported
Akita University Hospital
Akita, Japan
Site recruitment: Not reported
Kyushu University Hospital
Fukuoka, Japan
Site recruitment: Not reported
Kagoshiha University Hospital
Kagoshima, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pediatric Teduglutide Registry

ClinicalTrials.gov · NCT04832087 · Registry updated: 2023-12-11

Condition / research focus: Short Bowel Syndrome
Sponsor: Boston Children's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2021-05-18. Completion: 2023-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: Gattex

Where the study takes place — 1 listed sites

Boston Children's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients

ClinicalTrials.gov · NCT04290429 · Registry updated: 2023-11-29

Condition / research focus: Graft Versus Host Disease
Sponsor: University of Freiburg
Countries with listed sites: Germany
Registry dates and results: Start: 2017-12-06. Completion: 2019-12-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)

Where the study takes place — 1 listed sites

Medical Center University of Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome

ClinicalTrials.gov · NCT04883606 · Registry updated: 2023-08-31

Condition / research focus: Short Bowel Syndrome
Sponsor: Takeda
Countries with listed sites: Spain
Registry dates and results: Start: 2022-01-26. Completion: 2023-07-24 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease

ClinicalTrials.gov · NCT04877431 · Registry updated: 2023-07-19

Condition / research focus: Short Bowel Syndrome
Sponsor: Takeda
Countries with listed sites: Argentina
Registry dates and results: Start: 2020-11-05. Completion: 2023-06-05 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

IC Projects
Buenos Aires, Argentina
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV

ClinicalTrials.gov · NCT02431325 · Registry updated: 2023-06-12

Condition / research focus: HIV
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2015-12. Completion: 2021-01-21 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: Gattex
Placebo (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004

ClinicalTrials.gov · NCT03596164 · Registry updated: 2023-03-15

Condition / research focus: Short Bowel Syndrome
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2018-07-09. Completion: 2022-01-13 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)
Syringe (device)
Needle (device)
Vial Adapter for Device (device)

Where the study takes place — 5 listed sites

Hiroshima University Hospital
Hiroshima, Hiroshima, Japan
Site recruitment: Not reported
Hyogo College of Medicine Hospital
Hyōgo, Japan
Site recruitment: Not reported
Tohoku University Hospital
Miyagi-Ken, Japan
Site recruitment: Not reported
Osaka University Hospital
Osaka, Japan
Site recruitment: Not reported
Yokohama Municipal Citizen's Hospital
Yokohama, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications

ClinicalTrials.gov · NCT03953170 · Registry updated: 2023-02-23

Condition / research focus: Ileostomy - Stoma
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Countries with listed sites: United States
Registry dates and results: Start: 2022-06-02. Completion: 2022-12-29 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: Gattex
Placebo (drug)

Where the study takes place — 1 listed sites

Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

50 matching registry records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:42 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4CompletedINTERVENTIONAL

Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition

ClinicalTrials.gov · NCT04344717 · Registry updated: 2026-10-15

Condition / research focus: Short Bowel Syndrome; Anticoagulation
Sponsor: Universitaire Ziekenhuizen KU Leuven
Countries with listed sites: Belgium
Registry dates and results: Start: 2020-12-20. Completion: 2025-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Apixaban single dose (drug) — also listed as: Eliquis single dose
Apixaban steady-state (drug) — also listed as: Eliquis steady-state

Where the study takes place — 1 listed sites

University Hospitals Leuven
Leuven, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)

ClinicalTrials.gov · NCT05561647 · Registry updated: 2026-10-05

Condition / research focus: Short Bowel Syndrome (SBS)
Sponsor: Takeda
Countries with listed sites: United States
Registry dates and results: Start: 2013-08-01. Completion: 2026-08-26 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

No Intervention (other)

Where the study takes place — 1 listed sites

Takeda Pharmaceuticals, U.S.A., Inc.
Cambridge, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableActive, not recruitingOBSERVATIONAL

Registry for Participants With Short Bowel Syndrome

ClinicalTrials.gov · NCT01990040 · Registry updated: 2026-09-23

Condition / research focus: Short Bowel Syndrome
Sponsor: Shire
Countries with listed sites: United States
Registry dates and results: Start: 2014-06-23. Completion: 2032-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Shire
Lexington, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Active, not recruitingINTERVENTIONAL

A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

ClinicalTrials.gov · NCT06973304 · Registry updated: 2026-09-08

Condition / research focus: Short Bowel Syndrome
Sponsor: Takeda
Countries with listed sites: China
Registry dates and results: Start: 2025-06-26. Completion: 2027-07-28 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: TAK-633, A16AX08, Revestive, Gattex

Where the study takes place — 4 listed sites

Beijing Tsinghua Changgung Hospital
Changping, Beijing Municipality, China
Site recruitment: Not reported
Peking Union Medical College Hospital
Dongcheng, Beijing Municipality, China
Site recruitment: Not reported
Affiliated Jinling Hospital, Medical School of Nanjing University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Zhongshan Hospital, Xiamen University
Siming, Xiamen, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study of Teduglutide in Japanese People With Short Bowel Syndrome

ClinicalTrials.gov · NCT05023382 · Registry updated: 2026-08-07

Condition / research focus: Short Bowel Syndrome
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2021-09-01. Completion: 2026-07-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: TAK-633, Revestive

Where the study takes place — 1 listed sites

Takeda Selected Site
Tokyo, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Not yet recruitingINTERVENTIONAL

Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED)

ClinicalTrials.gov · NCT07537686 · Registry updated: 2026-04-17

Condition / research focus: Environmental Enteric Dysfunction
Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
Countries with listed sites: No country reported
Registry dates and results: Start: 2026-07-01. Completion: 2027-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide 0.05 dose (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome

ClinicalTrials.gov · NCT07319832 · Registry updated: 2026-03-13

Condition / research focus: Short Bowel Syndrome (SBS)
Sponsor: Takeda
Countries with listed sites: China
Registry dates and results: Start: 2026-03-05. Completion: 2027-09-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

No Intervention (other)

Where the study takes place — 4 listed sites

Guangzhou Women And Children's Medical Center
Guangzhou, Guangdong, China
Site recruitment: Not yet recruiting
Shanghai Children's Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not yet recruiting
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Recruiting
Children's Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Site recruitment: Not yet recruiting

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

TED_ORG: Study on Short Bowel Syndrome

ClinicalTrials.gov · NCT07400783 · Registry updated: 2026-02-10

Condition / research focus: Short Bowel Syndrome (SBS)
Sponsor: Meyer Children's Hospital IRCCS
Countries with listed sites: Italy
Registry dates and results: Start: 2024-10-30. Completion: 2026-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (ALX-0600) (drug)
No Treatment Added (other)

Where the study takes place — 1 listed sites

Aou Meyer IRCSS
Florence, Florence, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients

ClinicalTrials.gov · NCT03562130 · Registry updated: 2025-09-11

Condition / research focus: Short Bowel Syndrome
Sponsor: Assistance Publique - Hôpitaux de Paris
Countries with listed sites: France
Registry dates and results: Start: 2018-07-02. Completion: 2020-07-13 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)

Where the study takes place — 1 listed sites

Hôpital Necker - Enfants malades
Paris, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

ClinicalTrials.gov · NCT05371028 · Registry updated: 2025-04-06

Condition / research focus: Short Bowel Syndrome (SBS)
Sponsor: Takeda
Countries with listed sites: Canada
Registry dates and results: Start: 2023-09-23. Completion: 2025-02-19 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Non-interventional Study (other)

Where the study takes place — 1 listed sites

Innomar Strategies
Oakville, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)

ClinicalTrials.gov · NCT02954458 · Registry updated: 2025-03-28

Condition / research focus: Short Bowel Syndrome
Sponsor: Shire
Countries with listed sites: Belgium · Canada · Finland · Italy · United Kingdom · United States
Registry dates and results: Start: 2017-01-09. Completion: 2020-11-05 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TED (drug)
SOC (other)
Syringe (device)
Needle (device)

Where the study takes place — 22 listed sites

Childrens Hospital Los Angeles - RHU
Los Angeles, California, United States
Site recruitment: Not reported
Mattel Children's Hospital UCLA
Los Angeles, California, United States
Site recruitment: Not reported
UCSF Benioff Children's Hospital
San Francisco, California, United States
Site recruitment: Not reported
Georgetown Children's Research Network
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Riley Hospital for Children
Indianapolis, Indiana, United States
Site recruitment: Not reported
Boston Children's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
The Nebraska Medical Center
Omaha, Nebraska, United States
Site recruitment: Not reported
Columbia Unversity Medical Center
New York, New York, United States
Site recruitment: Not reported
Children's Hosp. at Montefiore
The Bronx, New York, United States
Site recruitment: Not reported
Duke Medical Center
Durham, North Carolina, United States
Site recruitment: Not reported
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Site recruitment: Not reported
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Texas Children's Hospital
Houston, Texas, United States
Site recruitment: Not reported
Seattle Children's Hospital
Seattle, Washington, United States
Site recruitment: Not reported
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, United States
Site recruitment: Not reported
Cliniques Universitaires Saint-Luc
Brussels, Woluwe-Saint-Lambert, Belgium
Site recruitment: Not reported
Walter C. Mackenzie Health Science Centre
Edmonton, Alberta, Canada
Site recruitment: Not reported
The Hospital for Sick Children
Toronto, Ontario, Canada
Site recruitment: Not reported
Helsingin yliopistollinen keskussairaala
Helsinki, Finland
Site recruitment: Not reported
Ospedale Pediatrico Bambino Gesu
Roma, Italy
Site recruitment: Not reported
Great Ormond Children's Hosp
London, Greater London, United Kingdom
Site recruitment: Not reported
Birmingham Children's Hospital
Birmingham, West Midlands, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

ClinicalTrials.gov · NCT02949362 · Registry updated: 2025-03-19

Condition / research focus: Short Bowel Syndrome
Sponsor: Shire
Countries with listed sites: United Kingdom · United States
Registry dates and results: Start: 2016-12-09. Completion: 2020-07-14 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)
SOC (other)

Where the study takes place — 11 listed sites

Childrens Hospital Los Angeles - RHU
Los Angeles, California, United States
Site recruitment: Not reported
Mattel Children's Hospital UCLA
Los Angeles, California, United States
Site recruitment: Not reported
Riley Hospital for Children
Indianapolis, Indiana, United States
Site recruitment: Not reported
Boston Children's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
Children's Mercy Hospitals and Clinics
Kansas City, Missouri, United States
Site recruitment: Not reported
Children's Hospital at Montefiore
The Bronx, New York, United States
Site recruitment: Not reported
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Site recruitment: Not reported
Texas Children's Hospital
Houston, Texas, United States
Site recruitment: Not reported
Seattle Children's Hospital
Seattle, Washington, United States
Site recruitment: Not reported
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, United States
Site recruitment: Not reported
Great Ormond Children's Hospital
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older

ClinicalTrials.gov · NCT05027308 · Registry updated: 2024-05-16

Condition / research focus: Short Bowel Syndrome
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2022-01-04. Completion: 2023-09-27 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: TAK-633

Where the study takes place — 6 listed sites

University of Tsukuba Hospital
Tsukuba, Ibaraki, Japan
Site recruitment: Not reported
Tohoku University Hospital
Sendai, Miyagi, Japan
Site recruitment: Not reported
Showa University Hospital
Shinagawa-ku, Tokyo, Japan
Site recruitment: Not reported
Akita University Hospital
Akita, Japan
Site recruitment: Not reported
Kyushu University Hospital
Fukuoka, Japan
Site recruitment: Not reported
Kagoshiha University Hospital
Kagoshima, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pediatric Teduglutide Registry

ClinicalTrials.gov · NCT04832087 · Registry updated: 2023-12-11

Condition / research focus: Short Bowel Syndrome
Sponsor: Boston Children's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2021-05-18. Completion: 2023-08-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: Gattex

Where the study takes place — 1 listed sites

Boston Children's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients

ClinicalTrials.gov · NCT04290429 · Registry updated: 2023-11-29

Condition / research focus: Graft Versus Host Disease
Sponsor: University of Freiburg
Countries with listed sites: Germany
Registry dates and results: Start: 2017-12-06. Completion: 2019-12-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)

Where the study takes place — 1 listed sites

Medical Center University of Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study With Teduglutide (Revestive®) in Adults With Short Bowl Syndrome

ClinicalTrials.gov · NCT04883606 · Registry updated: 2023-08-31

Condition / research focus: Short Bowel Syndrome
Sponsor: Takeda
Countries with listed sites: Spain
Registry dates and results: Start: 2022-01-26. Completion: 2023-07-24 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease

ClinicalTrials.gov · NCT04877431 · Registry updated: 2023-07-19

Condition / research focus: Short Bowel Syndrome
Sponsor: Takeda
Countries with listed sites: Argentina
Registry dates and results: Start: 2020-11-05. Completion: 2023-06-05 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

IC Projects
Buenos Aires, Argentina
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV

ClinicalTrials.gov · NCT02431325 · Registry updated: 2023-06-12

Condition / research focus: HIV
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2015-12. Completion: 2021-01-21 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: Gattex
Placebo (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004

ClinicalTrials.gov · NCT03596164 · Registry updated: 2023-03-15

Condition / research focus: Short Bowel Syndrome
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2018-07-09. Completion: 2022-01-13 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug)
Syringe (device)
Needle (device)
Vial Adapter for Device (device)

Where the study takes place — 5 listed sites

Hiroshima University Hospital
Hiroshima, Hiroshima, Japan
Site recruitment: Not reported
Hyogo College of Medicine Hospital
Hyōgo, Japan
Site recruitment: Not reported
Tohoku University Hospital
Miyagi-Ken, Japan
Site recruitment: Not reported
Osaka University Hospital
Osaka, Japan
Site recruitment: Not reported
Yokohama Municipal Citizen's Hospital
Yokohama, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3WithdrawnINTERVENTIONAL

Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications

ClinicalTrials.gov · NCT03953170 · Registry updated: 2023-02-23

Condition / research focus: Ileostomy - Stoma
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Countries with listed sites: United States
Registry dates and results: Start: 2022-06-02. Completion: 2022-12-29 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Teduglutide (drug) — also listed as: Gattex
Placebo (drug)

Where the study takes place — 1 listed sites

Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →